These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Thrombophlebitis of cephalic vein in the left forearm related to infliximab infusion. Huang ZY; Lin L; Tang Q; Wang YF J Dig Dis; 2016 Nov; 17(11):773-776. PubMed ID: 27598885 [No Abstract] [Full Text] [Related]
4. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study. Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928 [TBL] [Abstract][Full Text] [Related]
5. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. Verma AM; Patel A; Subramanian S; Smith PJ Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534 [No Abstract] [Full Text] [Related]
6. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease. Ma D; Wong W; Aviado J; Rodriguez C; Wu H Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population. Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416 [TBL] [Abstract][Full Text] [Related]
8. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. Clarkston K; Tsai YT; Jackson K; Rosen MJ; Denson LA; Minar P J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):68-74. PubMed ID: 31232885 [TBL] [Abstract][Full Text] [Related]
9. Use of infliximab in pediatric patients with inflammatory bowel disease. Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127 [TBL] [Abstract][Full Text] [Related]
10. The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation. Nhu QM; Chiao H; Moawad FJ; Bao F; Konijeti GG Am J Gastroenterol; 2018 Aug; 113(8):1261-1263. PubMed ID: 29895980 [No Abstract] [Full Text] [Related]
11. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632 [TBL] [Abstract][Full Text] [Related]
12. [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary]. Veres G; Szabó D; Várkonyi A; Tari B; Polgár M; B Kovács J; Horváth A; Tomsits E; Tokodi I; Bodánszky H; Dezsofi A; Szakos E; Vass N; Ruszinkó V; Kovács M; Müller KE; Arató A Orv Hetil; 2010 Jan; 151(5):179-83. PubMed ID: 20083466 [TBL] [Abstract][Full Text] [Related]
13. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease. Papamichael K; Karatzas P; Mantzaris GJ J Crohns Colitis; 2016 Mar; 10(3):371-2. PubMed ID: 26546496 [No Abstract] [Full Text] [Related]
14. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Jahnsen J; Detlie TE; Vatn S; Ricanek P Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534 [TBL] [Abstract][Full Text] [Related]
15. [Remicade (infliximab) in the treatment of Crohn disease]. Brazier F; Delcenserie R; Dupas JL Presse Med; 2000 Sep; 29(16):1463-4. PubMed ID: 11039091 [No Abstract] [Full Text] [Related]
17. Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated. Allegretti JR; Canakis A; McClure E; Marcus J; Norton BA; Hamilton MJ; Winter RW; De Silva PS; Friedman S; Korzenik JR Inflamm Bowel Dis; 2021 Nov; 27(12):2031-2033. PubMed ID: 34142700 [No Abstract] [Full Text] [Related]
18. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease. Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062 [TBL] [Abstract][Full Text] [Related]
19. A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease. Gupta SR; Crandall WV; Donegan A; Johnson M; Drobnic B; Oates M; Boyle B; Maltz RM; Dotson JL J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):544-550. PubMed ID: 31219936 [TBL] [Abstract][Full Text] [Related]
20. Swift Efficacy with Infliximab 4 Years after Initial Standard Induction Therapy Followed by Severe Delayed Infusion Reaction in Crohn's Disease. Chiba M; Tsuji T; Nakane K; Obara Y; Komatsu M Inflamm Bowel Dis; 2020 Jan; 26(1):e4. PubMed ID: 31697829 [No Abstract] [Full Text] [Related] [Next] [New Search]